TISSIUM is developing and commercialising a synthetic polymer platform, based on a proprietary polymer family with properties including the ability to conform to, and integrate with, surrounding tissue. The technology has several applications in drug delivery.
74 rue du Faubourg Saint-Antoine
Phone / ContactT: +33 1 76 21 72 28
E: [email protected]
TISSIUM is rapidly developing and commercialising a synthetic polymer platform to address clinical needs. The company’s platform, which has applications in drug delivery, is based on a proprietary polymer family with properties including the ability to conform to, and integrate with, surrounding tissue to enable natural healing. Furthermore, the modular design of the polymers enables customisation to match tissue-specific requirements for different therapeutic areas. The company also develops delivery and activation devices for enhanced performance and usability of its family of polymers.
Its technology platform was developed at The Massachusetts Institute of Technology (Cambridge, MA, US), Harvard Medical School (Boston, MA, US), and Brigham and Women’s Hospital (Boston).
TISSIUM is a privately owned life sciences company based in Paris, France.